4575 Stock Overview
CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CanBas Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥442.00 |
| 52 Week High | JP¥1,871.00 |
| 52 Week Low | JP¥411.00 |
| Beta | -0.53 |
| 1 Month Change | -11.25% |
| 3 Month Change | -53.03% |
| 1 Year Change | -74.61% |
| 3 Year Change | -0.67% |
| 5 Year Change | -57.50% |
| Change since IPO | -88.58% |
Recent News & Updates
Shareholder Returns
| 4575 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | -5.6% | -5.2% | -2.2% |
| 1Y | -74.6% | -30.4% | 29.7% |
Return vs Industry: 4575 underperformed the JP Biotechs industry which returned -30.4% over the past year.
Return vs Market: 4575 underperformed the JP Market which returned 29.7% over the past year.
Price Volatility
| 4575 volatility | |
|---|---|
| 4575 Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in JP Market | 8.3% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4575's share price has been volatile over the past 3 months.
Volatility Over Time: 4575's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 12 | Takumi Kawabe | www.canbas.co.jp |
CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd.
CanBas Co., Ltd. Fundamentals Summary
| 4575 fundamental statistics | |
|---|---|
| Market cap | JP¥8.09b |
| Earnings (TTM) | -JP¥1.07b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.4x
P/E RatioIs 4575 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4575 income statement (TTM) | |
|---|---|
| Revenue | JP¥0 |
| Cost of Revenue | JP¥486.00m |
| Gross Profit | -JP¥486.00m |
| Other Expenses | JP¥588.00m |
| Earnings | -JP¥1.07b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 10, 2024
| Earnings per share (EPS) | -59.59 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4575 perform over the long term?
See historical performance and comparison